Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00215514 · ClinicalTrials.gov registry record · Early Phase 1
Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma
A Early Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 25
- Enrollment target
NCT00215514: Completed Early Phase 1 study, sponsored by Dana-Farber Cancer Institute.
NCT00215514 is a Early Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 25 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00215514, a Early Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The main purpose of this trial is to determine how well patients with gastric or gastroesophageal junction adenocarcinoma respond to chemotherapy with epirubicin, cisplatin and 5-fluorouracil followed by continuous infusion 5-fluorouracil chemotherapy given along with radiation therapy.
Interventions
- DRUG Cisplatin
- DRUG 5-Fluorouracil (5-FU)
- DRUG Epirubicin
- PROCEDURE Radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2000-09 |
| Est. Completion | 2014-07 |
| Phase | Early Phase 1 |
What the finished NCT00215514 record still lists
NCT00215514 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 4 interventions - of which Cisplatin is the first listed.
NCT00215514 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00215514 about?
NCT00215514 is a clinical study titled "Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma". The main purpose of this trial is to determine how well patients with gastric or gastroesophageal junction adenocarcinoma respond to chemotherapy with epirubicin, cisplatin and 5-fluorouracil followed by continuous infusion 5-fluorouracil chemotherapy given along with radiation therapy.
What is the current status of trial NCT00215514?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 25 participants. The study started on 2000-09. Estimated completion is 2014-07.
What interventions are being tested in trial NCT00215514?
The interventions under investigation include: Cisplatin (DRUG), 5-Fluorouracil (5-FU) (DRUG), Epirubicin (DRUG), Radiation (PROCEDURE).
Who is sponsoring clinical trial NCT00215514?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00215514's enrollment target sits among peer trials
25 1000th of 2000 higher than 965 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia